Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

Bio-Thera had entered into an exclusive licensing agreement with STADA Arzneimittel AG to commercialize BAT2506 in the European Union (UK), the United Kingdom (UK), Switzerland, and selected other ...

There are currently four monoclonal antibodies available that are directed against TNF: infliximab, adalimumab, golimumab and certolizumab. All of these agents are efficacious in RA, with clinical ...

BAT2506 is a proposed biosimilar to Simponi® which is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule. Binding of golimumab to TNF ...

AVT05 is a biosimilar candidate to Johnson & Johnson's (JNJ) Simponi and Simponi Aria, also known by their generic name, golimumab, which are approved to treat a variety of inflammatory conditions.

Immunotherapy. 2012;4(11):1167-1179. Up to half the patients on anti-TNF-α therapies have inadequate responses. Substantial inter- and even intra-individual variations in the pharmacokinetics of ...